IL149568A0 - RECOMBINANT β-L-IDURONIDASE, METHODS FOR PRODUCING DISEASES CAUSED BY DEFICIENCIES THEREOF - Google Patents

RECOMBINANT β-L-IDURONIDASE, METHODS FOR PRODUCING DISEASES CAUSED BY DEFICIENCIES THEREOF

Info

Publication number
IL149568A0
IL149568A0 IL14956800A IL14956800A IL149568A0 IL 149568 A0 IL149568 A0 IL 149568A0 IL 14956800 A IL14956800 A IL 14956800A IL 14956800 A IL14956800 A IL 14956800A IL 149568 A0 IL149568 A0 IL 149568A0
Authority
IL
Israel
Prior art keywords
iduronidase
methods
recombinant
deficiencies
diseases caused
Prior art date
Application number
IL14956800A
Other languages
English (en)
Original Assignee
Biomarin Pharmaceuticals Harbo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceuticals Harbo filed Critical Biomarin Pharmaceuticals Harbo
Publication of IL149568A0 publication Critical patent/IL149568A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01014—Chitinase (3.2.1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01075—Glucan endo-1,6-beta-glucosidase (3.2.1.75)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL14956800A 1999-11-12 2000-11-09 RECOMBINANT β-L-IDURONIDASE, METHODS FOR PRODUCING DISEASES CAUSED BY DEFICIENCIES THEREOF IL149568A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/439,923 US6426208B1 (en) 1999-11-12 1999-11-12 Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
PCT/US2000/031293 WO2002004616A1 (en) 1999-11-12 2000-11-09 RECOMBINANT α-L-IDURONIDASE, METHODS FOR PRODUCING AND PURIFYING THE SAME AND METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES THEREOF

Publications (1)

Publication Number Publication Date
IL149568A0 true IL149568A0 (en) 2002-11-10

Family

ID=23746702

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14956800A IL149568A0 (en) 1999-11-12 2000-11-09 RECOMBINANT β-L-IDURONIDASE, METHODS FOR PRODUCING DISEASES CAUSED BY DEFICIENCIES THEREOF
IL149568A IL149568A (en) 1999-11-12 2002-05-09 Alpha-El-Iduronidaz I recombined a purified human
IL192078A IL192078A (en) 1999-11-12 2008-06-11 Use of recombinant human α – L – IDURONIDASE in drug preparation

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL149568A IL149568A (en) 1999-11-12 2002-05-09 Alpha-El-Iduronidaz I recombined a purified human
IL192078A IL192078A (en) 1999-11-12 2008-06-11 Use of recombinant human α – L – IDURONIDASE in drug preparation

Country Status (15)

Country Link
US (3) US6426208B1 (xx)
EP (2) EP1332206B1 (xx)
JP (3) JP2004502456A (xx)
CN (2) CN1420924B (xx)
AT (2) ATE342964T1 (xx)
AU (2) AU773663B2 (xx)
BR (1) BRPI0015533B8 (xx)
CA (1) CA2391098C (xx)
DE (2) DE60031456T2 (xx)
ES (2) ES2324727T3 (xx)
HK (2) HK1057059A1 (xx)
IL (3) IL149568A0 (xx)
MX (1) MXPA02004742A (xx)
WO (1) WO2002004616A1 (xx)
ZA (1) ZA200203619B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569661B1 (en) * 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6585971B1 (en) * 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
CA2438750A1 (en) * 2001-02-20 2002-08-29 Uab Research Foundation Aminoglycoside treatment for lysosomal storage diseases
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
AU2004268207A1 (en) * 2003-08-21 2005-03-10 Q Therapeutics, Inc. Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
WO2007065273A1 (en) * 2005-12-08 2007-06-14 The University Of British Columbia Mucopolysaccharidosis (mps) diagnostic methods, systems, kits and assays associated therewith
WO2013192317A2 (en) 2012-06-19 2013-12-27 University Of Florida Research Foundation, Inc. Compositions and methods for treating diabetes
WO2008116171A1 (en) * 2007-03-21 2008-09-25 Raptor Pharmaceutical Inc. Cyclic receptor-associated protein (rap) peptides
US20090053786A1 (en) 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2093085B1 (en) * 2008-02-21 2012-05-02 Fiat Group Automobiles S.p.A. Glass supporting assembly for a motor vehicle door with an unframed upper edge
HUE034850T2 (en) 2008-05-07 2018-03-28 Biomarin Pharm Inc Lysosomal targeting peptides and their use
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
DE102011102170B4 (de) 2011-05-20 2024-06-06 Vitesco Technologies GmbH Einspritzvorrichtung zur Einspritzung eines Fluids
IN2015KN00596A (xx) 2012-08-10 2015-07-17 Osio Corp D B A Yolia Health
KR102346455B1 (ko) * 2013-03-15 2022-01-04 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｍｐｓｉ 치료를 위한 조성물 및 방법
EP3411488A1 (en) 2016-02-03 2018-12-12 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
BR112019015482A2 (pt) * 2017-01-31 2020-03-31 Regenxbio Inc. Método para tratar um indivíduo humano diagnosticado com mucopolissacaridose i (mps i)
BR112020000063A2 (pt) 2017-07-06 2020-07-14 The Trustees Of The University Of Pennsylvania terapia gênica mediada por aav9 para tratamento de mucopolissacaridose tipo i
AU2018335752A1 (en) 2017-09-22 2020-03-12 Christian HINDERER Gene therapy for treating Mucopolysaccharidosis type ii
CN107699590A (zh) * 2017-10-13 2018-02-16 成都中医药大学 一种制备重组人α‑L‑艾杜糖醛酸酶的方法
US20220023434A1 (en) 2018-12-19 2022-01-27 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods
CN110577559B (zh) * 2019-08-19 2023-02-17 江西科技师范大学 α-L-艾杜糖醛酸酶测定用荧光糖苷酶底物的合成方法
WO2022145449A1 (ja) * 2021-01-04 2022-07-07 国立大学法人徳島大学 ライソゾームを標的とした新規ｄｄｓの開発
CN115109790A (zh) * 2021-03-23 2022-09-27 北京据德医药科技有限公司 一种重组a-L-艾杜糖醛酸普酶及其制备方法
CN114181318B (zh) * 2021-11-08 2023-08-01 四川大学 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用
CN115161284B (zh) * 2022-07-04 2024-07-09 无锡多宁生物科技有限公司 一种lmh悬浮细胞复苏培养方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281225A (xx) 1961-07-20
GB1029548A (en) 1963-07-17 1966-05-11 Amagasaki Iron & Steel Mfg Co Corrugated roofing sheet
US3472931A (en) 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3891757A (en) 1971-11-11 1975-06-24 Alza Corp Anaesthetic topical and percutaneous administration with selected promoters
US5270051A (en) 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
JPH06504449A (ja) 1991-11-14 1994-05-26 ウイミンズ・アンド・チルドレンズ・ホスピタル 合成アルファ−ｌ−イズロニダーゼおよびそれをコード化する遺伝子配列
US5278051A (en) * 1991-12-12 1994-01-11 New York University Construction of geometrical objects from polynucleotides
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
GB9807464D0 (en) 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
CA2328518A1 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof

Also Published As

Publication number Publication date
ATE430193T1 (de) 2009-05-15
US20060286087A1 (en) 2006-12-21
CN101407796A (zh) 2009-04-15
JP2005046154A (ja) 2005-02-24
EP1792983A1 (en) 2007-06-06
WO2002004616A1 (en) 2002-01-17
CA2391098A1 (en) 2002-01-17
CN1420924A (zh) 2003-05-28
CA2391098C (en) 2007-10-23
IL149568A (en) 2010-04-29
IL192078A (en) 2011-06-30
ES2273748T3 (es) 2007-05-16
JP3857705B2 (ja) 2006-12-13
BRPI0015533B8 (pt) 2021-05-25
BRPI0015533B1 (pt) 2020-12-08
AU8463501A (en) 2002-01-21
JP2004502456A (ja) 2004-01-29
DE60031456T2 (de) 2007-08-23
EP1332206B1 (en) 2006-10-18
EP1332206A1 (en) 2003-08-06
US20030013179A1 (en) 2003-01-16
ATE342964T1 (de) 2006-11-15
EP1792983B1 (en) 2009-04-29
US7041487B2 (en) 2006-05-09
DE60031456D1 (de) 2006-11-30
ZA200203619B (en) 2003-07-30
HK1057059A1 (en) 2004-03-12
ES2324727T3 (es) 2009-08-13
JP2006312648A (ja) 2006-11-16
CN1420924B (zh) 2010-05-05
BR0015533A (pt) 2002-06-25
AU2004208651A1 (en) 2004-09-30
MXPA02004742A (es) 2005-09-08
US6426208B1 (en) 2002-07-30
AU773663B2 (en) 2004-06-03
HK1104836A1 (en) 2008-01-25
IL192078A0 (en) 2008-12-29
DE60042137D1 (de) 2009-06-10

Similar Documents

Publication Publication Date Title
IL149568A0 (en) RECOMBINANT β-L-IDURONIDASE, METHODS FOR PRODUCING DISEASES CAUSED BY DEFICIENCIES THEREOF
WO2002038775A3 (en) METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE
NZ507103A (en) Cell differentiation/proliferation and maintenance factor and uses thereof
GB9606187D0 (en) Production of vanillin
AU1520195A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
GB2407821A (en) Generation of neural stem cells from undifferentiated human embryonic stem cells
WO2003104270A3 (en) GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES
HU9602114D0 (en) Chloropyrimide intermediates
WO1999058691A3 (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
NO20002702L (no) Tienopyrimidiner
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
WO2001083722A3 (en) Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
BG105014A (en) Ureas and carbamates of n-heterocyclic carboxylic acids and carboxylic acid isosteres
WO2003056897A3 (en) Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
IL128028A0 (en) Treatment of psychotic disorders
IL114185A0 (xx)
ES2180433A1 (es) Empleo de celulas madre hematopoyeticas en la generacion de celulas madre neurales.
GB9425071D0 (en) Chondrocyte cell lines
HRP20030714A2 (en) Use of thiolutin dioxide and its derivatives in the manufacture of a medicament, and a process for the preparation thereof
TW370564B (en) The process for producing rice Cn/Zn-superoxide dismutase
UA67666A (en) Method for treating parkinson's disease